jump to navigation

C-Boot released new mobile intermittent pneumatic compression device June 10, 2009

Posted by israelhealthcare in Medical Device.
Tags: , ,
add a comment

Compression therapy products provider C-Boot has released a new mobile Intermittent Pneumatic Compression (IPC) Device. The C-Boot Elastic model enhances the effectiveness of C-Boot in treating Chronic Venous Insufficiency (CVI), venous ulcers, Lymphedema, and other conditions that require compression therapy, including the enhancement of blood circulation during recovery from coronary artery bypass graft surgery and orthopedic hip and knee replacements.

“The new C-Boot Elastic is an important step in our strategy to become a leading, manufacturer of innovative wearable compression devices,” said Ronen Castro, C-Boot CEO. “One of the enhancements we made to the Elastic model is in the foot portion of the C-Boot. The Foot portion is now designed ergonomically as elastic sock and is perfectly fitted with any size of foot or width. These changes have made C-Boot Elastic very easy to wear with almost every regular shoe and provide better comfort to the patient.”

C-Boot develops and manufactures advanced compression therapy products powered automatically by energy generated from the patient’s body. C-Boot products are mainly prescribed by dermatologists, orthopedics, wound-care experts, physiotherapists, cardiac and vascular experts for treating various of medical conditions, like, DVT prevention, Ulcers and Lymphedema.

Sponsored Links – Olive Oil for Scalp Psoriasis | Epilepsy Alert Device

Advertisements

Biosurgery startup LifeBond raised $8 million from Pitango and Omrix founder Taub June 3, 2009

Posted by israelhealthcare in Biosurgery.
Tags: , ,
add a comment

Biosurgery products development startup LifeBond has raised $8 million in a second financing round led by Pitango Venture Capital and Robert Taub, founder and former CEO of Omrix Biopharmaceuticals, which recently acquired by Johnson & Johnson for $438 million. Existing investors: GlenRock Israel, Leon Recanati’s investment company, and Zitelman Group, also participating in this round.

LifeBond is developing surgical sealants and hemostats intended for preventing leakage and bleeding. Proceeds from the round will be used for the completion of the pre-clinical and clinical phases of the Company’s initial product: LifeSeal SLR, a sealant indicated for reinforcement of gastro-intestinal anastomoses. The company anticipates that LifeSeal SLR will reach the market in 2011, pending regulatory approval in the U.S., Europe and Israel.

LifeBond was founded in 2007 by Ishay Attar, the current LifeBond CEO, Orahn Preiss-Bloom, LifeBond VP Operations, and Nir Mashkif. The company received seed funding from the Trendlines Israel Fund, followed by a $1.5 million round A financing round led by GlenRock Israel. The Company’s headquarters and research center are located in Caesarea Industrial Park.

Sponsored Links – Intermittent Pneumatic Compression | Psoriasis Treatment | Test Management Tool for Mantis Bugs Tracker